Pharsight

Drugs that contain Telbivudine

1. Tyzeka patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US6395716 NOVARTIS β-L-2′-deoxy-nucleosides for the treatment of hepatitis B
Aug, 2019

(4 years ago)

US7795238 NOVARTIS β-L-2′-deoxy-nucleosides for the treatment of hepatitis B
Aug, 2019

(4 years ago)

US6566344 NOVARTIS β-L-2′-deoxy-nucleosides for the treatment of hepatitis B
Aug, 2019

(4 years ago)

US6444652 NOVARTIS β-L-2'-deoxy-nucleosides for the treatment of hepatitis B
Aug, 2019

(4 years ago)

US6569837 NOVARTIS β-L-2′-deoxy pyrimidine nucleosides for the treatment of hepatitis B
Oct, 2020

(3 years ago)

US7858594 NOVARTIS Crystalline and amorphous forms of beta-L-2′-deoxythymidine
Sep, 2023

(8 months ago)

US7589079 NOVARTIS Crystalline and amorphous forms of beta-L-2′-deoxythymidine
Sep, 2023

(8 months ago)

Drug Exclusivity Drug Exclusivity Expiration
New Chemical Entity Exclusivity(NCE) Oct 25, 2011
M(M-124) Jan 28, 2016

NCE-1 date: 25 October, 2010

Market Authorisation Date: 25 October, 2006

Treatment: Treatment of chronic hepatitis b in adult patients; Treatment of chronic hepatitis b in adult patients with evidence of viral replication and either evidence of persistent elevations in serum aminotra...

Dosage: TABLET;ORAL; SOLUTION;ORAL

More Information on Dosage

TYZEKA family patents

Family Patents